Compare PLCE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLCE | ONCY |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 98.7M |
| IPO Year | 1997 | 2002 |
| Metric | PLCE | ONCY |
|---|---|---|
| Price | $2.84 | $0.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $7.33 |
| AVG Volume (30 Days) | 448.1K | ★ 1.6M |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.71 |
| 52 Week High | $9.56 | $1.51 |
| Indicator | PLCE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 56.82 |
| Support Level | N/A | $0.90 |
| Resistance Level | $3.81 | $1.06 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 2.59 | 75.14 |
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.